Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076979 | 1.00 | CACNA1G (0.42) | CACNA1GMCHR1HTR2CHTR2AHTR2B | |
| SCHEMBL5871268 | 0.90 | HTR1A (0.45) | HTR2CHTR2AHTR1AHTR1DHTR1B | |
| SCHEMBL5871353 | 0.87 | HTR1A (0.51) | CACNA1GMCHR1HTR2CHTR2AHTR2B | |
| SCHEMBL5871542 | 0.86 | CACNA1G (0.45) | CACNA1GMCHR1HTR2CHTR2AHTR2B | |
| SCHEMBL5871576 | 0.85 | MCHR1 (0.42) | CACNA1GMCHR1HTR1AHTR1DHTR1B | |
| SCHEMBL5871652 | 0.85 | SCD (0.45) | MCHR1HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL5871468 | 0.84 | SIGMAR1 (0.44) | CACNA1GHTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL5871355 | 0.84 | HTR1A (0.49) | CACNA1GHTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL5871038 | 0.83 | HTR2A (0.44) | MCHR1HTR2CHTR2AHTR2BHTR1A | |
| SCHEMBL5871263 | 0.83 | MCHR1 (0.43) | CACNA1GMCHR1HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541371-B2 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | claimed |
| US-20080027039-A1 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-31 | — | — | US | claimed |
| US-7541371-B2 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20080027039-A1 | Method for treating a motor neuron disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027039-A1 | Method for treating a motor neuron disease | SMN1; SMN2, NLN, SLC18A2 | CACNA1G 272/4885MCHR1 89/4885HTR2C 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.